公开(公告)号：US07247304B2

公开(公告)日：2007-07-24

申请号：US10379741

申请日：2003-03-05

Applicant: Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jørgen Peterson

Inventor： Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jørgen Peterson

IPC: A61K39/395

CPC classification number: C07K16/24 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  Y10S514/885

Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-15（例如人IL-15）特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换而在能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US07153507B2

公开(公告)日：2006-12-26

申请号：US10226615

申请日：2002-08-23

Applicant: Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard

Inventor： Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard

IPC: A61K39/395 ,  C12N5/12

CPC classification number: C07K16/244 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/24 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US06951646B1

公开(公告)日：2005-10-04

申请号：US09744176

申请日：1999-07-20

Applicant: Christian Reiter ,  Francois Habersetzer ,  Anne Fournillier ,  Christian Trepo ,  Claude Desgranges ,  Genevieve Inchauspe

Inventor： Christian Reiter ,  Francois Habersetzer ,  Anne Fournillier ,  Christian Trepo ,  Claude Desgranges ,  Genevieve Inchauspe

IPC: G01N33/53 ,  A61K39/29 ,  A61K39/395 ,  A61P31/12 ,  C07K14/18 ,  C07K16/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/10 ,  C12P21/08 ,  C12R1/91 ,  G01N33/569 ,  G01N33/576 ,  G01N33/577 ,  A61K39/12 ,  A61K39/42 ,  C12Q1/70

CPC classification number: G01N33/5767 ,  A61K2039/505 ,  C07K16/109 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

Abstract translation: 描述了特异性识别HCV糖蛋白E2的构象依赖性表位的新型抗体，并且能够中和E2蛋白与敏感细胞的结合。 此外，提供了由上述抗体识别的抗原和表位以及编码所述抗体的多核苷酸。 还提供了包含所述多核苷酸的载体以及转化的宿主细胞及其在所述抗体的产生中的用途。 此外，提供药物和诊断组合物，其包含任何上述抗体，抗原，表位，多核苷酸，载体或细胞。 进一步描述了上述抗体，抗原，多核苷酸和载体在过继性免疫治疗中的用途，优选用于治疗或预防肝移植期间的HCV感染。

公开(公告)号：US20040208873A1

公开(公告)日：2004-10-21

申请号：US10738120

申请日：2003-12-16

Applicant: MEDAREX, INC. ,  GENMAB A/S

Inventor： Jessica Teeling ,  Paul Parren ,  Ole Baadsgaard ,  Debra Hudson ,  Jorgen Petersen

IPC: A61K039/395 ,  C07K016/24

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6869

Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-8结合的分离的人单克隆抗体（例如人IL-8）。 人抗体可以通过进行V-D-J重组和同种型转换，在能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物，杂交瘤和产生人抗体的转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。